OR WAIT null SECS
Aenova has opened a new building for the production of highly potent APIs in Germany.
Contract development and manufacturing organization (CDMO) Aenova has opened a new building for the production of highly potent APIs at its Regensburg site in Germany, it was announced in a June 23, 2023 press release.
With this investment, worth a total of €25 million, Aenova will be able to increase its development and production capacities for cytotoxics and cytostatics and meet the growing market demand for these ingredients. The new building comprises four stories with a total building area of more than 4000 m2 and includes production and packaging facilities for highly potent tablets along with associated laboratories, development, storage, and social rooms.
“Producing billions of tablets and capsules each year, Aenova is a partner of choice for novel product solutions as well as commercial high-volume manufacturing,” said Oliver Schmied, managing director at the Aenova site in Regensburg, in the press release. “A particularly unique selling point is that we offer production flexibility using harmonized production equipment, enabling small to large batches from 0.5 to 500 kg for development, [clinical trial materials], scale up, and commercial batches.”
“Within the overall investments of the Aenova Group, the new building for highly potent APIs in Regensburg is an essential strategic building block,” added Jan Kengelbach, CEO of the Aenova Group, in the press release. “As a development and manufacturing partner, we are thus a reliable and agile CDMO for our customers in the promising market segment of highly potent active ingredients.”